Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody

Etentamig is an investigational B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager, composed of a low-affinity CD3 binding domain, potentially reducing cytokine release syndrome (CRS) and infections, a high-avidity bivalent BCMA-binding domain, and retained FcRn binding supporting monthly (Q4W) dosing after a single step-up dose (SUD). We report long-term efficacy and safety from the ongoing, open-label, phase 1 (dose escalation/expansion; NCT03933735) and Arm A of the phase 1b (NCT05650632) studies of etentamig in adult patients with relapsed/refractory multiple myeloma, triple-class exposure, and ≥3 prior lines of therapy (LoT). In phase 1, patients received etentamig 60 mg Q4W or 40 mg Q3W, and in phase 1b, a SUD on Day 1 and 60 mg Q4W on Day 4. Among 146 patients (median age: 68 years; median [range] prior LoT: 4 [3-23]), median follow-up was 13 months (range: 1-48). Objective responses and ≥ very good partial responses occurred in 66% and 54% of patients. Median duration of response and progression-free survival were not reached. Pooled data suggest etentamig has a manageable safety profile, with Grade 3/4 neutropenia and infection occurring in 38% and 23% of patients. In phase 1b Arm A (n=23), overall CRS incidence was 30% (26% Grade 1; 4% Grade 2) with modified dexamethasone premedication and 1 SUD; median onset was 22.3 hours (range: 5.5-29.6) hours, with resolution in 20.7 hours (range: 1.8-131.7). Etentamig's molecular design may be associated with the observed clinical efficacy and tolerability while also potentially supporting extended dosing intervals.

Authors

Institutions

Publication Details

Journal
Blood
Published
2026-11-16
DOI
https://doi.org/10.1182/blood.2026034590
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody

Katja Christina Weisel, Shaji Kunnathu Kumar, Saurabh Chhabra, Emma J Searle et al.
6 links
Blood
Multiple Myeloma Research and Treatments
article

Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody

Katja Christina Weisel, Shaji Kunnathu Kumar, Saurabh Chhabra, Emma J Searle, Cesar Rodriguez, Hila Magen, Anita D’Souza, Muhamed Baljević, Neha Korde, Rajvineeth Kumar Pothacamury, Chetasi Talati, Alfred Chung, Aarif Ahsan, Anders Svensson, Peter VOORHEES, Eben Isaac Lichtman, Claudie Hecquet, Hana Safah, Ravi Vij, John T. Mckay, Valerie Robinson, Carli Allendorf, Hira Mian
article en

Abstract

Etentamig is an investigational B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager, composed of a low-affinity CD3 binding domain, potentially reducing cytokine release syndrome (CRS) and infections, a high-avidity bivalent BCMA-binding domain, and retained FcRn binding supporting monthly (Q4W) dosing after a single step-up dose (SUD). We report long-term efficacy and safety from the ongoing, open-label, phase 1 (dose escalation/expansion; NCT03933735) and Arm A of the phase 1b (NCT05650632) studies of etentamig in adult patients with relapsed/refractory multiple myeloma, triple-class exposure, and ≥3 prior lines of therapy (LoT). In phase 1, patients received etentamig 60 mg Q4W or 40 mg Q3W, and in phase 1b, a SUD on Day 1 and 60 mg Q4W on Day 4. Among 146 patients (median age: 68 years; median [range] prior LoT: 4 [3-23]), median follow-up was 13 months (range: 1-48). Objective responses and ≥ very good partial responses occurred in 66% and 54% of patients. Median duration of response and progression-free survival were not reached. Pooled data suggest etentamig has a manageable safety profile, with Grade 3/4 neutropenia and infection occurring in 38% and 23% of patients. In phase 1b Arm A (n=23), overall CRS incidence was 30% (26% Grade 1; 4% Grade 2) with modified dexamethasone premedication and 1 SUD; median onset was 22.3 hours (range: 5.5-29.6) hours, with resolution in 20.7 hours (range: 1.8-131.7). Etentamig's molecular design may be associated with the observed clinical efficacy and tolerability while also potentially supporting extended dosing intervals.

Blood
University of North Carolina at Chapel Hill (US), Atrium Health Wake Forest Baptist (US), Our Lady of the Lake Regional Medical Center (US), Froedtert Hospital (US), Mayo Clinic (US), Memorial Sloan Kettering Cancer Center (US), Tel Aviv University (IL), University of California, San Francisco (US), Washington University in St. Louis (US), Sheba Medical Center (IL), University of Manchester (GB), AbbVie (United States) (US), University Medical Center Hamburg-Eppendorf (DE), Mayo Clinic in Arizona (US), The Christie NHS Foundation Trust (GB), Wake Forest Baptist Comprehensive Cancer Center (US), UNC Lineberger Comprehensive Cancer Center (US), Medical College of Wisconsin Cancer Center (US), Wake Forest University Health Sciences (US), Wake Forest University (US), University of Arkansas for Medical Sciences (US), McMaster University (CA)
Good health and well-being
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon